Get the Stockscreener App
676.54
2.52%
-17.48
After Hours:
680.00
3.46
+0.51%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc stock is traded at $676.54, with a volume of 3.57M.
It is down -2.52% in the last 24 hours and up +2.74% over the past month.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
See More
Previous Close:
$694.02
Open:
$691.7
24h Volume:
3.57M
Relative Volume:
1.30
Market Cap:
$250.15B
Revenue:
$45.20B
Net Income/Loss:
$6.87B
P/E Ratio:
37.20
EPS:
18.1888
Net Cash Flow:
$6.75B
1W Performance:
-2.86%
1M Performance:
+2.74%
6M Performance:
+31.63%
1Y Performance:
+19.28%
1-Day Range:
$674.10
$703.20
1-Week Range:
$661.30
$705.78
52-Week Range:
$435.27
$705.78
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc
Sector
Industry
Phone
(781) 622-1000
Address
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
676.54 | 250.15B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
229.75 | 161.51B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
401.37 | 57.86B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
173.89 | 49.02B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
278.32 | 45.81B | 16.63B | 1.39B | 2.12B | 8.0674 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-26 | Upgrade | UBS | Neutral → Buy |
| Sep-03-26 | Initiated | CLSA | Outperform |
| Jun-26-26 | Resumed | Bernstein | Mkt Perform |
| Jun-11-26 | Initiated | Piper Sandler | Neutral |
| Jun-03-26 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-02-26 | Resumed | Wolfe Research | Outperform |
| May-15-26 | Resumed | RBC Capital Mkts | Sector Perform |
| Mar-27-26 | Initiated | DZ Bank | Buy |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Dec-09-25 | Initiated | Goldman | Buy |
| Dec-08-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Dec-01-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-11-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-19-25 | Initiated | William Blair | Outperform |
| Jul-24-25 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-11-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jul-09-25 | Downgrade | UBS | Buy → Neutral |
| Jan-10-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-23-24 | Initiated | Scotiabank | Sector Perform |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Oct-01-24 | Initiated | Stephens | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Mar-18-24 | Resumed | Citigroup | Neutral |
| Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-06-23 | Resumed | Citigroup | Buy |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
| Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-04-23 | Reiterated | Barclays | Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-26-22 | Resumed | Barclays | Overweight |
| Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-16-21 | Initiated | The Benchmark Company | Buy |
| Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Initiated | Goldman | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-14-20 | Initiated | Morgan Stanley | Overweight |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
| Jul-07-20 | Reiterated | Needham | Buy |
| Apr-23-20 | Reiterated | Needham | Buy |
| Jan-31-20 | Reiterated | Needham | Buy |
| Jan-22-20 | Initiated | Credit Suisse | Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-25-19 | Reiterated | Needham | Buy |
| Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
| May-30-19 | Initiated | Wolfe Research | Outperform |
| May-23-19 | Reiterated | Needham | Strong Buy |
| Apr-22-19 | Reiterated | Needham | Strong Buy |
| Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc Stock (TMO) Latest News
RBC Raises Price Target on Thermo Fisher Scientific to $730 From $580, Keeps Sector Perform Rating - www.marketscreener.com
Deutsche Bank Adjusts Thermo Fisher Scientific PT to $750 From $720, Maintains Buy Rating - www.marketscreener.com
Stifel Adjusts Price Target on Thermo Fisher Scientific to $775 From $650 - marketscreener.com
Barclays Adjusts Price Target on Thermo Fisher Scientific to $775 From $750 - marketscreener.com
Company News for Oct 22, 2026 - Zacks Investment Research
TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum - Yahoo Finance
Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth - BioSpectrum Asia
Thermo Fisher Scientific (TMO) Stock Faces A Q3 Earnings Disconnect - Yahoo Finance
Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $701.64, Implies 2% Upside - TradingView
Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore (NYSE:TMO) - Seeking Alpha
Thermo Fisher Scientific Inc (TMO) (Q3 2026) Earnings Call Highl - GuruFocus
Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors - Yahoo Finance
Thermo Fisher Scientific Tops Q3 2026 Profit Forecast With $6.68 EPS - AlphaStreet
Thermo Fisher Scientific Gains 4.3% on Q3 Earnings Beat - 24/7 Wall St.
Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Why Is Thermo Fisher Scientific Stock Trading Higher Today?Thermo Fisher Scientific (NYSE:TMO) - Benzinga
Thermo Fisher Scientific Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Thermo Fisher reports strong 3rd-quarter results - WFMZ.com
Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings - Benzinga
Thermo Fisher Scientific Reports Third Quarter 2026 Results - BioSpace
Thermo Fisher stock gains on Q3 beat (update) (TMO:NYSE) - Seeking Alpha
Thermo Fisher Scientific Tops Q3 2026 Profit Forecast With $6.68 EPS - AlphaStreet
Thermo Fisher Q3: The Recovery Is Real, And I'm Still Buying (NYSE:TMO) - Seeking Alpha
Thermo Fisher Q3 2026 earnings show adjusted EPS up 15% to $6.68 - Quartz
Thermo Fisher Scientific Reports 9% Revenue Growth as Third-Quarter Earnings Beat Estimates - Yahoo Finance
Thermo Fisher Scientific Inc. reports results for the quarter ended September 30Earnings Summary - TradingView
Thermo Fisher Scientific Q3 2026 Earnings Call Transcript - Benzinga
Thermo Fisher Scientific Releases Q3 2026 Earnings Results - AlphaStreet
Is Thermo Fisher Scientific Inc (TMO) Overvalued After Q3 Earnin - GuruFocus
Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research
Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance Singapore
Thermo Fisher Scientific Reports Third Quarter 2026 Results - Business Wire
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again - Zacks Investment Research
Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings - Benzinga
Thermo Fisher Scientific Inc. stock: results due October 21 ahead of Xetra open - ad-hoc-news.de
Thermo Fisher (TMO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Thermo Fisher Scientific Inc. stock falls Monday, underperforms market - MarketWatch
Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala - GlobeNewswire Inc.
Thermo Fisher Scientific Inc. expected to post earnings of $6.40 a shareEarnings Preview - TradingView
Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus - Zacks Investment Research
Clinical Trial Supplies Market Forecasts Growth from $5.7 Billion (2025) to $10.7 Billion by 2033, Profiling Thermo Fisher Scientific, Catalent, Almac Group, UPS Healthcare & 6 Other Key Players - GlobeNewswire Inc.
Thermo Fisher Scientific (TMO) Is Building A Bigger Role In Precision Diagnostics - Yahoo Finance
Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ - The National Law Review
Thermo Fisher Scientific (TMO) Stock Gets Fair Value Bump After Q2 Driven Analyst Target Increases - Yahoo Finance
Learn Why The Bull Case For Thermo Fisher Scientific Stock Could Change Following Omics Demand Growth - Yahoo Finance
Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery - Yahoo Finance
Academic and Government Spending Powers Thermo Fisher (TMO) - Yahoo Finance
Thermo Fisher Scientific (TMO) Q3 2026 Preview: EPS Est. $6.40, Reports October 21 - AlphaStreet
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Thermo Fisher Scientific Inc Stock (TMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Thermo Fisher Scientific Inc Stock (TMO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pettiti Gianluca | Officer |
Aug 31 '26 |
Proposed Sale |
614.38 |
4,133 |
2,539,233 |
0 |
| Pettiti Gianluca | President & COO |
Aug 31 '26 |
Sale |
614.38 |
4,133 |
2,539,233 |
23,216 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Sale |
627.05 |
275 |
172,439 |
123,925 |
| CASPER MARC N | Chairman & CEO |
Aug 24 '26 |
Option Exercise |
309.63 |
275 |
85,148 |
124,200 |
| CASPER MARC N | Officer |
Aug 24 '26 |
Proposed Sale |
627.05 |
275 |
172,438 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 21 '26 |
Sale |
626.92 |
10,000 |
6,269,153 |
123,925 |
| CASPER MARC N | Officer |
Aug 21 '26 |
Proposed Sale |
626.91 |
10,000 |
6,269,123 |
0 |
| CASPER MARC N | Officer |
Aug 20 '26 |
Proposed Sale |
629.27 |
10,000 |
6,292,653 |
0 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
| CASPER MARC N | Chairman & CEO |
Aug 20 '26 |
Option Exercise |
309.63 |
10,000 |
3,096,300 |
133,925 |
1.76%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):